Your session is about to expire
← Back to Search
PCNA Inhibitor AOH1996 for Cancer
Study Summary
This trial is testing AOH1996 to see if it can help patients with solid tumors that haven't responded to other treatments. AOH1996 may work by blocking some of the enzymes needed for cell growth.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Who is running the clinical trial?
Media Library
- You are taking warfarin (a blood thinner medication).You are taking dietary or herbal supplements.You are currently participating in or have recently used any other experimental treatments or medications.You have difficulty taking medication by mouth, such as swallowing pills or experiencing ongoing nausea or vomiting.You are expected to live for more than 3 months.You have a type of cancer that has not responded to regular treatments, or you have chosen not to receive standard treatments.You are currently taking other medications or undergoing other treatments that may interfere with the study.
- Group 1: Treatment (PCNA inhibitor AOH1996)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are medical centers currently signing up participants for this clinical investigation?
"Affirmative. Clinicaltrials.gov data indicates that the medical trial, which was first advertised on August 12th 2022, is still recruiting participants. Approximately 8 patients must be sourced from 2 different clinical sites."
Has the Food and Drug Administration officially sanctioned Treatment (PCNA inhibitor AOH1996)?
"As this is a preliminary Phase 1 trial, the safety of treatment (PCNA inhibitor AOH1996) was deemed to be low and thus received a score of 1."
To what extent is recruitment ongoing for this research endeavor?
"Yes, the information posted on clinicaltrials.gov appears to confirm that this medical experiment is actively seeking participants. This trial had its inception on August 12th 2022 and was recently updated on September 29th 2022. They are looking for 8 individuals across 2 research sites."
What are the principal aims of this exploration?
"The primary endpoint of this medical trial is to evaluate dose-limiting toxicities over a 30 day period post-treatment. Secondary endpoints include response rate (as assessed with RECIST v1), progression free survival, and time to treatment failure."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Most responsive sites:
- HonorHealth Research Institute: < 48 hours
Typically responds via
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger